[{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Sosei Heptares solves structure of the agonist bound orexin OX2 receptor and identifies small molecule binding site using unique StaR® technology and structure-based approach.